Men shouldn't be screened for prostate cancer with a common blood test, a widely followed federal advisory panel recommended on Monday. But the report isn't likely to quell a dispute about whether the test's risks outweigh its potential benefits.

The U.S. Preventive Services Task Force recommended a "D" grade for prostate-specific-antigen, or PSA, testing which has been widely used for almost two decades to screen men for prostate cancer. Previously the task force had recommended against PSA testing...